Onconova Announces Four Presentations from Rigosertib Clinical Trials in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting & Exposition
November 05, 2018 08:30 ET
|
Onconova Therapeutics, Inc.
Oral presentation on Saturday will feature efficacy and safety data from Expanded Phase 2 trial of rigosertib in combination with AzacitidineThree Poster presentations to feature pharmacokinetics,...
Onconova Therapeutics, Inc. to Provide Corporate Update and Third Quarter 2018 Financial Results
November 01, 2018 08:30 ET
|
Onconova Therapeutics, Inc.
Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Tuesday, November 13, 2018 NEWTOWN, Pa., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a...
Onconova Therapeutics Announces Issuance of a New U.S. Patent for Rigosertib
October 17, 2018 08:30 ET
|
Onconova Therapeutics, Inc.
Granted claims cover both oral and injectable formulations of RigosertibNewly issued US patent 10,098,862 extends protection for Rigosertib into 2037Equivalent coverage is being sought worldwide and,...
Onconova Therapeutics to Present Update at the 2018 BIO Investor Forum in San Francisco
October 10, 2018 08:30 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Oct. 10, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics Announces Reverse Stock Split
September 25, 2018 09:16 ET
|
Onconova Therapeutics, Inc.
Reverse split intended primarily to increase the per share bid price of Onconova's common stock and satisfy the Nasdaq Capital Market continued listing requirement NEWTOWN, Pa., Sept. 25, 2018 ...
Onconova Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference in New York City
August 28, 2018 08:30 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics Announces Plan for Expanding Rigosertib Clinical Trials for Patients with Myelodysplastic Syndromes (MDS) to South America with Pint Pharma
August 21, 2018 08:30 ET
|
Onconova Therapeutics, Inc.
Pint Pharma to facilitate expansion of Phase 3 INSPIRE trial to Argentina, Chile, and Brazil in preparation for future studies of oral rigosertib NEWTOWN, Pa., Aug. 21, 2018 (GLOBE NEWSWIRE) --...
Onconova Therapeutics Reports Business Highlights and Financial Results for Second Quarter 2018
August 14, 2018 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on developing rigosertib, a novel small molecule drug...
Onconova Therapeutics, Inc. to Provide Corporate Update and Second Quarter 2018 Financial Results
August 07, 2018 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics Announces Promotion for Steven M. Fruchtman, M.D.
June 21, 2018 08:00 ET
|
Onconova Therapeutics, Inc.
New Role as the President involves leadership of the entire product portfolioPromotion reflects progress of Rigosertib to key data milestones NEWTOWN, Pa., June 21, 2018 (GLOBE NEWSWIRE) --...